{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Register online
|
Log in
|
My Prescrire
Issue contents
Current issue
Last 12 issues
All issues
Topics
Annual Prescrire Awards
Advancing healthcare policy
Positions
Mediator° - the criminal trial
Drugs to avoid: 2022 update
Spotlight
About Prescrire
Who are we?
How we work
AMP: non-profit
Financing
No conflicts of interest
Where to find us
About Prescrire International
Testimonials
Prescrire events
A global network
Offers
Subscribe now
Solidarity Subscription Rate
Subscribers: register online
Prescrire's other products
Free Special Edition
Sign up to receive the newsletter
english.prescrire.org
>
Topics
>
Advancing healthcare policy
>
The Medicines in Europe Forum: actions by the network
>
Back to the list of themes
Advancing healthcare policy
The Medicines in Europe Forum: actions by the network
Advancing healthcare policy
Chronological recap of actions
Actions presented by theme
Back to the list of themes
Overview
Actions in 2017
Health technology assessment: joint response to the EU Commission Consultation (1/2017)
Actions in 2016
Open letter to the EC on "Strengthening the Balance in the Pharmaceutical Systems" (9/2016)
Member States ought to support the EU Presidency's vision on access to affordable medicines (4/2016)
Trilogue Meetings: increase transparency to level the playing field (3/2016)
Representatives of civil society call for an R&D framework driven by global public health needs (2/2016)
Why You Should Be Concerned About TTIP and Access to Medicines (2/2016)
Actions in 2015
A PRIME example of how EMA is pushing for accelerated market approvals, but at what cost for patients? (12/2015)
European medicines agencies must address independence and transparency problems (7/2015)
EU directive on trade secrets: amendments needed! (3/2015)
EU Clinical Trials Regulation: EMA steers away from transparency (2/2015)
European Directive on trade secrets: A threat to access to public health data (2/2015)
Actions in 2014
EU trade secrets directive: statement by a multi-sectoral NGO coalition (12/2014)
EMA softens its conflict of interest policy (11/2014)
EMA's final policy on access to clinical data (10/2014)
EU Pharmacovigilance public hearings (10/2014)
Clinical trials regulation: a major advance in transparency (9/2014)
INNs of biologics and biosimilars: consistency must be preserved (9/2014)
A step backwards on pharmaceutical policy at the EU Commission (9/2014)
EMA's policy on pharmacovigilance data (9/2014)
Providing "scientific advice" to pharma industry undermines the independence of regulatory authorities (7/2014)
'Investor-to-state dispute settlement' in EU–US trade deal threatens access to affordable medicines (7/2014)
EMA's new policy on access to clinical data (6/2014)
Backpedalling on EMA’s "proactive publication of clinical-data" draft policy (5/2014)
The US-EU Trade Agreement Proposals by the pharmaceutical industry undermine European public policy making and public health (3/2014)
EU Regulation on clinical trials: close to the finish line (3/2014)
Actions in 2013
"Biosimilars": the EMA makes a timid shift towards a more pragmatic approach (10/2013)
Medical devices legislation: regaining the trust of European citizens (5/2013)
Amended proposal for a new directive on transparency measures regulating the prices of medicinal products: still threatening Member States' health systems (4/2013)
Clinical trials regulation: choose transparency! (4/2013)
New proposal for a Regulation on clinical trials: Protect human subjects; Strengthen citizens' right to information (2/2013)
Actions in 2012
French sunshine act: is the French government backing down on industry gifts? (10/2012)
Medical devices: an entire overhaul of the medical legislation is needed (10/2012)
European Medicines Agency and pharmacovigilance: no to a fee-for-service system (9/2012)
Black triangle for medicines: Positive move but poor implementation plan (8/2012)
Proposal for a new Directive on transparency of measures regulating the prices of medicinal products: EC oversteps its role (7/2012)
Access to EU's documents is essential (6/2012)
EU Parliament says no and no again to EMA (5/2012)
Fighting "counterfeit medicines" should not be used as a pretext to track sales data (4/2012)
Actions in 2011
Revised proposals on "information" to patients: Still an open door to advertising (10/2011)
Response to HMA/EMA on identification of commercially confidential information (8/2011)
Packaging for non-prescription medicines: Prescrire's response to EMA (6/2011)
EMA suggestions on comparative clinical trials fall back behind ethical and scientific standards (3/2011)
Actions in 2008-2010
Final proposals on pharmacovigilance: Some progress, but a missed opportunity (12/2010)
Towards DTC advertising for prescription drugs? The autumn will be crucial (continued) (11/2010)
Towards DTC advertising of prescription drugs in Europe? (7/2010)
EMA's policy on conflict of interest: improvements needed (6/2010)
EMA road map: independence should be the priority (4/2010)
DTC Communication? Europeans deserve better (3/2010)
Medicines placed under the DG-SANCO’s competence (12/09)
EU Commission's proposals endanger the population (10/2009)
Future Commission: need for change in health goods governance (10/09)
EMEA transparency policy falls short: a weak and irresponsible project (9/2009)
EU Commission's proposals on pharmacovigilance dismantle the entire system (6/2009)
Legal proposals on "information" to patients by pharmaceutical companies (3/09)
Pharmaceutical package: a short-sighted vision that puts patients at risk (3/2009)
Joint open letter on the "Pharmaceutical Package" (11/08)
Recast of Medical Devices Directives (7/08)
"Patient information" by pharmaceutical companies: unanimous opposition (6/08)
Pharmacovigilance : overwhelming opposition to the EC proposals (5/2008)
Time to act for Patient Safety (5/08)
EC's "Information" proposal serves firms, not patients (4/08)
New European pharmacovigilance legislation: getting it right (2/08)
Actions in 2005-2007
EC puts companies before public health (7/07)
Pharmaceutical Forum's working group: a sham consultation (5/07)
Joint Declaration "Relevant information for citizens" (12/06)
Advanced therapy medicinal products (4/06)
Draft regulation on medicines for paediatric use (7/05)
Medicines for paediatric use: take the time to improve an important project (5/05)
Medicines for paediatric use (1/05)
The 2002-2004 campaign
About the MiEF
Back to the list of themes
Sitemap
|
Terms of use
|
Contact
|
Top of page
Prescrire
Your change of address has been received and will be processed promptly but will not appear instantaneously
Prescrire
Your message has been sent